← Back to Search

Vitamin

Nicotinamide riboside for COVID-19 (NIRVANA Trial)

Phase 2
Waitlist Available
Led By Kumar Sharma, MD
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days to 90 days

Summary

This trial will use NR to see if it can help improve NAD+ levels in people with COVID-19 and acute kidney injury. They will also be looking at the safety of using NR.

Eligible Conditions
  • COVID-19
  • Acute Kidney Failure
  • Acute Kidney Injury

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days to 90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days to 90 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Whole Blood NAD+ Level
Number of Participants With Adverse Events of Grade 3 or Higher
Occurrence of Thrombocytopenia
Secondary study objectives
Change in Area Under the Curve (AUC)
Change in Estimated Glomerular Filtration Rate (eGFR)
Change in Proteinuria
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Nicotinamide Riboside GroupExperimental Treatment1 Intervention
Nicotinamide riboside 250mg capsules will be administered 2 capsules twice daily for 10 days
Group II: Placebo GroupPlacebo Group1 Intervention
Placebo capsules will be administered 2 capsules twice daily for 10 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotinamide riboside
2021
Completed Phase 3
~390

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center at San AntonioLead Sponsor
476 Previous Clinical Trials
92,947 Total Patients Enrolled
4 Trials studying COVID-19
353 Patients Enrolled for COVID-19
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,449 Previous Clinical Trials
4,332,439 Total Patients Enrolled
4 Trials studying COVID-19
5,918 Patients Enrolled for COVID-19
Kumar Sharma, MD4.229 ReviewsPrincipal Investigator - UT Health San Antonio
Medical School - Armed Forces Medical College, Bachelor of Medicine, Bachelor of Surgery
Prince George's Hospital Center, Residency in Surgery
1Patient Review
I found his behaviour to be inappropriate and unprofessional. He made sexual advances and hugged me at the end of the appointment.
~6 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top